Inclusion Criteria:

- Metastatic pancreatic carcinoma (excluding pancreatic endocrine tumors); histologic
confirmation of either the primary or metastatic site.

- ECOG performance status of < 1

- > 4 weeks since completion of previous chemotherapy

- > 4 weeks since participation in any investigational drug study

- Peripheral neuropathy of grade < 1

- Patients must have failed a gemcitabine-containing regimen administered in the
metastatic, adjuvant, or locally advanced setting.

- Absolute neutrophil count (ANC) > 1,500/mm3

- Hemoglobin > 9.0gm/dl

- Platelets > 100,000/mm3

- Total bilirubin < 2.0mg/dl

- AST and alkaline phosphatase < 5 x upper limit of normal (ULN)

- Albumin > 2.5gm/dl

- CA 19-9 > 1.5 x ULN

Exclusion Criteria:

- Prior therapy with taxane or with epidermal growth factor receptor (EGFR) inhibitors

- More than one prior chemotherapy treatment

- Clinically significant cardiac disease

- Major surgery within 4 weeks of the start of study treatment

- Evidence of central nervous system (CNS) metastases or carcinomatous meningitis or
history of uncontrolled seizures, central nervous system disorders.

- Uncontrolled serious medical or psychiatric illness

- Pregnant or breast-feeding women

- Other active malignancy

- Inability to swallow tablets or evidence of a gastrointestinal malabsorption syndrome

- Known severe hypersensitivity to Iressa

- Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital,
or St. John's wort.

- History of severe hypersensitivity reaction to drugs formulated with polysorbate 80

- Any evidence of clinically active interstitial lung disease

- Ascites requiring paracentesis